25 completed, 20 unknown, 13 active not recruiting, 12 recruiting. 18 Phase 4, 17 Phase 3, 14 Phase 2, 10 Not applicable, 5 Phase 1.
Follow Chronic Rhinosinusitis With Nasal Polyps: new trials by email Literature Review of Chronic Rhinosinusitis With Nasal Polyps trials Research Report on Chronic Rhinosinusitis With Nasal Polyps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps MG-K10, Placebo, Mometasone Furoate Nasal Spray - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 210 | 2026-10-27 | 2026-10-29 |
| Tezepelumab CRSwNP Real World Study (CREW Study) Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Not yet recruiting | AstraZeneca | 100 | 2026-10-01 | 2026-08-27 | |
| Thermosensitive Gel Nasal Spray With Stem Cell Exosomes, Mupirocin, and DNase I for Chronic Sinusitis Exosomes (hUC-MSC-Exo), Mupirocin, DNase I - Chronic Rhinosinusitis With Nasal Polyps | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital of Xinxiang Medical College | 108 | 2026-07-01 | 2026-06-09 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Withdrawn | Sanofi | 2026-05-08 | 2026-08-13 | |
| A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-04-24 | 2026-10-16 |
| A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients Other: Routine Clinical Care for CRSwNP - Chronic Rhinosinusitis With Nasal Polyps | Active not recruiting | AstraZeneca | 146 | 2026-03-19 | 2026-09-25 | |
| An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | Sanofi | 59 | 2026-03-12 | 2026-10-13 |
| A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis CM326 injection, Placebo of CM326 - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Not yet recruiting | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 212 | 2026-02-28 | 2026-02-19 |
| Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps SHR-1905 Injection, SHR-1905 Placebo Injection - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 280 | 2025-08-28 | 2025-11-17 |
| Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps increased dosing interval of biological therapy - Chronic Rhinosinusitis With Nasal Polyps | Phase 4 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 135 | 2025-06-05 | 2025-09-23 |
| Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study Lunsekimig, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis With Nasal Polyps | Phase 2 | Active not recruiting | Sanofi | 71 | 2025-05-12 | 2026-10-28 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | Sanofi | 231 | 2025-02-12 | 2026-10-21 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | Sanofi | 216 | 2025-02-06 | 2026-10-21 |
| Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma Tezepelumab - Asthma, Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Not yet recruiting | Dr. Andrew Thamboo, MD | 10 | 2025-01-01 | 2024-12-18 |
| Efficacy of Long-Term Low Dose Macrolide Therapy in Preventing Early Recurrence of Nasal Polyps After Endoscopic Sinus Surgery clarithromycin 250 mg - Chronic Rhinosinusitis With Nasal Polyps | Not applicable | Completed | Fatima Jinnah Medical University | 100 | 2025-01-01 | 2026-01-06 |
| Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). surgical arm, Mepolizumab 100 MG, combined arm - Chronic Rhinosinusitis With Nasal Polyps | Phase 4 | Recruiting | Instituto de Investigación Marqués de Valdecilla | 75 | 2024-12-31 | 2026-09-11 |
| A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | AstraZeneca | 181 | 2024-12-03 | 2026-10-07 |
| Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis (CRS). Sinonasal microbiome transplant procedure., Placebo saline transplant - Chronic Rhinosinusitis Without Nasal Polyps, Chronic Rhinosinusitis With Nasal Polyps | Phase 2 / Phase 3 | Recruiting | Region Skane | 50 | 2024-10-14 | 2025-09-22 |
| A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps GR1802, Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 228 | 2024-09-19 | 2026-10-29 |
| Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps Dupilumab, Placebo - Chronic Rhinosinusitis With Nasal Polyps, Asthma | Phase 4 | Unknown | Dr. Andrew Thamboo, MD | 60 | 2024-08-01 | 2024-08-16 |
Showing 20 of 80. Sign in to see all of them.
Nasal Polyps (15) · Asthma (11) · Disease (5) · Pulmonary Eosinophilia (2) · Rhinosinusitis (2) · Agnosia (1) · Allergic Fungal Sinusitis (1) · Asthma, Aspirin-Induced (1) · Dermatitis, Atopic (1) · Eosinophilia (1) · Nose Diseases (1) · Olfaction Disorders (1) · Otorhinolaryngologic Diseases (1) · Paranasal Sinus Diseases (1) · Patient Participation (1)
Respiratory Tract Diseases (27) · Pathological Conditions, Signs and Symptoms (20) · Nose Diseases (17) · Otorhinolaryngologic Diseases (17) · Hypersensitivity (15) · Hypersensitivity, Immediate (15) · Immune System Diseases (15) · Pathological Conditions, Anatomical (15) · Polyps (15) · Respiratory Hypersensitivity (14) · Lung Diseases (13) · Bronchial Diseases (12) · Lung Diseases, Obstructive (11) · Infections (6) · Pathologic Processes (5)
dupilumab (14) · mepolizumab (13) · Omalizumab (5) · tezepelumab (5) · Budesonide (4) · itepekimab (4) · Glucocorticoids (2) · Methylprednisolone (2) · Mometasone Furoate (2) · Prednisolone (2) · Surveys and Questionnaires (2) · Biological Products (1) · Biopsy (1) · Blood Specimen Collection (1) · Bronchoscopy (1)
Sanofi (10) · AstraZeneca (5) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (3) · Keymed Biosciences Co.Ltd (3) · Assiut University (2) · Beijing Tongren Hospital (2) · Centre hospitalier de l'Université de Montréal (CHUM) (2) · Christiane Haase (2) · Copenhagen University Hospital, Rigshospitalet (2) · Dr. Andrew Thamboo, MD (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Guangdong Hengrui Pharmaceutical Co., Ltd (2) · Johns Hopkins University (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Medical University of Vienna (2)
United States (19) · China (18) · Canada (12) · Poland (10) · Denmark (8) · Spain (8) · Belgium (7) · France (7) · United Kingdom (7) · Germany (6) · Hungary (6) · Italy (6) · Argentina (5) · Austria (4) · Czechia (4)
Luo Zhang (4) · Andrew Thamboo (2) · Geoffrey Mortuaire, MD (2) · Jean Kim, MD PhD (2) · Aly Ragaie (1) · Amin Javer, MD (1) · Brian Lipworth, MD (1) · Chengshuo Wang, Professor (1) · Christian Pedersen, MD (1) · Christian von Buchwald (1) · Christian von Buchwald, MD, DMSc, prof. (1) · Dehui Wang (1) · Dongdong Zhu, Professor (1)
PMID 10887619, PMID 30876830, PMID 31362741, PMID 31798645, PMID 32077450, PMID 32128424, PMID 33910399, PMID 34256031, PMID 35837739, PMID 37772436, PMID 38482462, PMID 38749694, PMID 39215351, PMID 39393433, PMID 39417152, PMID 39444257, PMID 40106374, PMID 40191526, PMID 40884290, PMID 41022848, PMID 41033334, PMID 41036707, PMID 42299713, PMID 42612655, PMID 42644458, PMID 42854989, PMID 42868896
2023 (1), 2025 (1), P01HL107202 (1)